+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Efficacies of different vancomycin dosing regimens against Staphylococcus aureus determined with a dynamic in vitro model



Efficacies of different vancomycin dosing regimens against Staphylococcus aureus determined with a dynamic in vitro model



Antimicrobial Agents and ChemoTherapy 38(10): 2480-2482



A dynamic in vitro model was used to assess four different vancomycin dosing regimens against Staphylococcus aureus. These regimens achieved peak drug concentrations of 48 micrograms/ml (single dose) and 30 micrograms/ml (dosed every 12 h) and constant concentrations of 16 and 8 micrograms/ml. Analysis of the area under the bacterial concentration-time curve, area under the first moment of the bacterial concentration-time curve, and bacterial elimination rate constant showed no difference in the rate or extent of bacterial killing. The optimal dosing method may be that which achieves the lowest area under the curve while concentrations are maintained above the MBC.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 008587059

Download citation: RISBibTeXText

PMID: 7840593

DOI: 10.1128/aac.38.10.2480


Related references

Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model. Journal of Antimicrobial ChemoTherapy 64(2): 364-369, 2009

Efficacies of vancomycin, arbekacin, and gentamicin alone or in combination against methicillin-resistant Staphylococcus aureus in an in vitro infective endocarditis model. Antimicrobial Agents and ChemoTherapy 47(12): 3768-3773, 2003

Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrobial Agents and ChemoTherapy 45(2): 454-459, 2001

Vancomycin and piperacillin-tazobactam against methicillin-resistant Staphylococcus aureus and vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model. Clinical Therapeutics 36(10): 1334-1344, 2016

Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model. Antimicrobial Agents and ChemoTherapy 54(12): 5115-5119, 2011

Preferential emergence of reduced vancomycin susceptibility in health care-associated methicillin-resistant Staphylococcus aureus isolates during continuous-infusion vancomycin therapy in an in vitro dynamic model. Antimicrobial Agents and ChemoTherapy 55(7): 3627-3630, 2011

Telavancin and vancomycin pharmacodynamics with Staphylococcus aureus in an in vitro dynamic model. Journal of Antimicrobial ChemoTherapy 62(5): 1065-1069, 2008

Ceftaroline pharmacodynamic activity versus community-associated and healthcare-associated methicillin-resistant Staphylococcus aureus, heteroresistant vancomycin-intermediate S. aureus, vancomycin-intermediate S. aureus and vancomycin-resistant S. aureus using an in vitro model. Journal of Antimicrobial ChemoTherapy 66(6): 1301-1305, 2011

Exploration of optimal dosing regimens of vancomycin in patients infected with methicillin-resistant Staphylococcus aureus by modeling and simulation. Journal of Clinical Pharmacy and Therapeutics 39(2): 196-203, 2014

Pharmacodynamics of vancomycin alone and in combination with gentamicin at various dosing intervals against methicillin-resistant Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model. Antimicrobial Agents and ChemoTherapy 41(11): 2497-2501, 1997

Evaluation of vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus and heterogeneously vancomycin-intermediate S. aureus in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations. Journal of Antimicrobial ChemoTherapy 63(1): 155-160, 2009

Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model. Journal of Antimicrobial ChemoTherapy 58(6): 1185-1192, 2006

Comparative efficacies of tedizolid phosphate, vancomycin, and daptomycin in a rabbit model of methicillin-resistant Staphylococcus aureus endocarditis. Antimicrobial Agents and ChemoTherapy 59(6): 3252-3256, 2016

Evaluation of the activities of different linezolid dosing regimens compared to levofloxacin and vancomycin against multi-drug resistant and vancomycin-tolerant Streptococcus pneumoniae in an in vitro pharmacodynamic model. Abstracts of the General Meeting of the American Society for Microbiology 101: 33-34, 2001

In vitro efficacies and resistance profiles of rifampin-based combination regimens for biofilm-embedded methicillin-resistant Staphylococcus aureus. Antimicrobial Agents and ChemoTherapy 57(11): 5717-5720, 2014